FGFR extracellular domain acidic region muteins
AssigneeFive Prime Therapeutics, Inc.
InventorsShannon Marshall, Deborah H. Charych, Ali Sadra
Life of this patent
Estimating the term…
Abstract
Fibroblast growth factor receptor (FGFR) extracellular domain (ECD) acidic region muteins that have been engineered to exhibit decreased tissue binding by increasing the number of acidic amino acid residues within the D1-D2 linker region are provided. Polynucleotides encoding FGFR ECD acidic region muteins are also provided. Methods of making FGFR ECD acidic region muteins, and methods of using such molecules to treat proliferative disorders, including cancers, disorders of angiogenesis, and macular degeneration, are also provided.
Claims9
A polypeptide comprising a fibroblast growth factor receptor 4 extracellular domain (FGFR4 ECD) D1-D2 linker chimera comprising a D1-D2 linker selected from an FGFR1 D1-D2 linker, an FGFR2 D1-D2 linker, and an FGFR3 D1-D2 linker, in place of the FGFR4 D1-D2 linker.
A method of treating cancer in a patient comprising administering to the patient an effective amount of (i) a polypeptide comprising an FGFR4 ECD D1-D2 linker chimera, or (ii) an FGFR4 ECD fusion molecule comprising an FGFR4 ECD D1-D2 linker chimera and a fusion partner.
Dependencies are inferred from the claim text.